CDRH stakeholders meeting
This article was originally published in The Gray Sheet
FDA Associate Commissioner for Strategic Management Linda Suydam and CDRH Director Bruce Burlington are members of an agency panel that will convene at an Aug. 18 public meeting on Sec. 406(b) of the FDA Modernization Act. The meeting, which is mandated under FDAMA, will be divided into three sections, including: Medical Device Users (Part One) and Health Organizations; Trade Associations/Standards Organizations; and Medical Device Users (Part Two) and Patients and Consumers. The meeting begins at 9:00 a.m. in the HHS Humphrey Building in Washington, D.C. FDA will hold a second public meeting on the issue on Sept. 14. For further information, contact Catherine Beck at 301/827-3443
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.